The continuous spectrum of glycaemic variability changes with pancreatic islet function: A multicentre cross-sectional study in China
- PMID: 36214297
- DOI: 10.1002/dmrr.3579
The continuous spectrum of glycaemic variability changes with pancreatic islet function: A multicentre cross-sectional study in China
Abstract
Aims: To investigate glycaemic variability (GV) patterns in patients with type 1 diabetes (T1D), type 2 diabetes (T2D), and latent autoimmune diabetes in adults (LADA).
Materials and methods: A total of 842 subjects (510 T1D, 105 LADA, 227 T2D) were enrolled and underwent 1 week of continuous glucose monitoring (CGM). Clinical characteristics and CGM parameters were compared among T1D, LADA, and T2D. LADA patients were divided into two subgroups based on glutamic acid decarboxylase autoantibody titres (≥180 U/mL [LADA-1], <180 U/mL [LADA-2]) and compared. The C-peptide cut-offs for predicting a coefficient of variation (CV) of glucose ≥36% and a time in range (TIR) > 70% were determined using receiver operating characteristic analysis.
Results: Twenty-seven patients (9 T1D, 18 T2D) were excluded due to insufficient CGM data. Sex, diabetes duration and HbA1c were comparable among the three groups. Fasting and 2-h postprandial C-peptide (FCP, 2hCP) increased sequentially across T1D, LADA, and T2D. T1D and LADA patients had comparable TIR and GV, whereas those with T2D had much higher TIR and lower GV (p < 0.001). The GV of LADA-1 was close to that of T1D, while the GV of LADA-2 was close to that of T2D. CP exhibited the strongest negative correlation with GV. The cut-offs of FCP/2hCP for predicting a CV ≥ 36% and TIR >70% were 121.6/243.1 and 128.9/252.8 pmol/L, respectively.
Conclusions: GV presented a continuous spectrum across T1D, LADA-1, LADA-2, and T2D. More frequent glucose monitoring is suggested for patients with impaired insulin secretion.
Clinical trail registration: Chinese Clinical Trial Registration (ChiCTR) website approved by WHO; http://www.chictr.org.cn/ - ChiCTR2200065036.
Keywords: β-cell function; continuous glucose monitoring; glycaemic variability; latent autoimmune diabetes in adults; type 1 diabetes; type 2 diabetes.
© 2022 John Wiley & Sons Ltd.
References
REFERENCES
-
- Diabetes Control and Complications Trial Research Group, Nathan DM , Genuth S , et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
-
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Lachin JM , Genuth S , Cleary P , Davis MD , Nathan DM . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-389
-
- Holman RR , Paul SK , Bethel MA , Matthews DR , Neil HAW . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. https://doi.org/10.1056/nejmoa0806470
-
- Orchard TJ , Nathan DM , Zinman B , et al., Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313(1):45-53. https://doi.org/10.1001/jama.2014.16107
-
- Beck RW , Connor CG , Mullen DM , Wesley DM , Bergenstal RM . The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care. 2017;40(8):994-999. https://doi.org/10.2337/dc17-0636
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous